Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction
- PMID: 7687622
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction
Abstract
Episialin (MUC1) is a mucin-like glycoprotein abundantly expressed on most carcinoma cells. As a result of its extended and rigid structure, it reduces intercellular adhesion. We investigated whether this antiadhesion function allows tumor cells expressing high levels of episialin to escape from immune recognition. To test this hypothesis, we transfected episialin-negative (episialin-) melanoma cells (A375) with the MUC1 cDNA-encoding episialin. The results demonstrated that episialin-positive (episialin+) melanoma cells were significantly less susceptible to lysis than episialin- melanoma cells by both alloantigen or rIL-2-stimulated cytotoxic effector cells. In addition, cold target inhibition experiments with episialin+ and episialin- cells clearly demonstrated preferential lysis of episialin- cells. Furthermore, antibody blocking studies showed that lysis of episialin+, but not of episialin-, melanoma cells was predominantly dependent on the leukocyte function-associated Ag-1/intracellular adhesion molecule adhesion route, suggesting that episialin+ target cells adhere less efficiently to effector cells than episialin- target cells. This notion was supported by the observation that conjugate formation of the effector cells with episialin+ target cells was significantly impaired. From these results we conclude that over-expression of episialin as found on many tumor cells may indeed affect efficient lysis by cytotoxic lymphocytes and thus may contribute to escape from immune surveillance.
Similar articles
-
Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes.J Immunol. 1993 Mar 1;150(5):1653-62. J Immunol. 1993. PMID: 7679690
-
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.Cancer Res. 1993 Jul 15;53(14):3343-8. Cancer Res. 1993. PMID: 7686816
-
Suppression of cellular aggregation by high levels of episialin.Cancer Res. 1992 Apr 15;52(8):2318-24. Cancer Res. 1992. PMID: 1559234
-
Functional aspects of three molecules associated with metastasis development in human malignant melanoma.Invasion Metastasis. 1989;9(6):338-50. Invasion Metastasis. 1989. PMID: 2574717 Review.
-
Is episialin/MUC1 involved in breast cancer progression?Cancer Lett. 1995 Mar 23;90(1):27-33. doi: 10.1016/0304-3835(94)03674-8. Cancer Lett. 1995. PMID: 7720039 Review.
Cited by
-
Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain.Br J Cancer. 2007 Oct 8;97(7):910-8. doi: 10.1038/sj.bjc.6603972. Epub 2007 Oct 2. Br J Cancer. 2007. PMID: 17912239 Free PMC article.
-
Mucins and blastocyst attachment.Rev Endocr Metab Disord. 2002 May;3(2):87-96. doi: 10.1023/a:1015446626671. Rev Endocr Metab Disord. 2002. PMID: 12007285 Review. No abstract available.
-
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.J Cell Biol. 1995 Apr;129(1):255-65. doi: 10.1083/jcb.129.1.255. J Cell Biol. 1995. PMID: 7698991 Free PMC article.
-
Transmembrane mucins as novel therapeutic targets.Expert Rev Endocrinol Metab. 2011 Nov;6(6):835-848. doi: 10.1586/eem.11.70. Expert Rev Endocrinol Metab. 2011. PMID: 22201009 Free PMC article.
-
Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.Immunology. 1999 Oct;98(2):213-9. doi: 10.1046/j.1365-2567.1999.00827.x. Immunology. 1999. PMID: 10610356 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous